Exhibiting at FOOD INGREDIENTS CHINA 2025

CSPC Pharmaceutical Group Co., Ltd. is one of China’s leading pharmaceutical conglomerates, headquartered in Shijiazhuang, Hebei Province. With a legacy that spans over eight decades, CSPC has transformed from a traditional chemical pharmaceutical enterprise into a modern biopharmaceutical innovator with global reach. The company is listed on the Hong Kong Stock Exchange (HKEX: 1093) and is part of the Hang Seng Index constituent stocks, reflecting its strong market position and investor confidence.

Core Business and Operations

CSPC specializes in the research, development, manufacturing, and marketing of a diverse portfolio of pharmaceutical products. The company’s core business is structured around innovative drugs, generic finished drugs, and bulk pharmaceuticals. It serves therapeutic areas such as central nervous system disorders, oncology, anti-infectives, cardiovascular diseases, and metabolic diseases.

With a focus on innovation-driven growth, CSPC has launched several first-in-class and best-in-class drugs in China. Notably, its flagship products include:

• NBP (Butylphthalide) for stroke and cerebral ischemia, a category-leading product in China.
• Jinyouli (PEG-rhG-CSF), the first PEGylated recombinant human granulocyte colony-stimulating factor in China.
• Keaili (Paclitaxel for injection - albumin-bound) for cancer treatment.
• Xuanning (Amlodipine Besylate) for hypertension.
• DuoMeisu (Doxorubicin Hydrochloride Liposome) for oncology use.

Specialisation and Unique Strengths

CSPC’s R&D-driven strategy is powered by more than 2,000 scientists across multiple R&D centers located in Shijiazhuang, Shanghai, and the United States. The company invests heavily in innovation, with R&D spending reaching HKD 4.07 billion in 2023, representing over 10% of its annual revenue.

Their proprietary CNS drug NBP was awarded the State Science and Technology Progress Award (First Class) by the Chinese government, highlighting CSPC’s pioneering contributions to neurological therapeutics.

The company also boasts over 20 products under clinical trials or pending approval, with a strong pipeline in oncology, immunology, and metabolic diseases.

Financials

CSPC Pharmaceutical Group reported the following key financial metrics for the fiscal year ending December 2023:

• Revenue: HKD 38.6 billion (approx. USD 4.9 billion)
• Net Profit: HKD 8.07 billion (approx. USD 1.02 billion)
• R&D Investment: HKD 4.07 billion
• Gross Margin: Approximately 62%

The company's financial strength underpins its sustained investments in innovation, infrastructure, and global expansion.

Global Shipments and Export Performance

According to export tracking platforms such as Volza and ImportYeti, CSPC has established a strong international presence. Notable international shipments include:

• Over 2,400 export shipments recorded in the last 24 months across 50+ countries, including the U.S., Japan, South Korea, Brazil, and various European and Southeast Asian nations.
• Exported pharmaceutical APIs such as Vitamin C, Caffeine, and antibiotics to top international buyers like GSK, Teva, and Fresenius.

These data points demonstrate CSPC’s credibility as a global pharmaceutical supplier with proven logistics capabilities.

Target Markets

CSPC’s primary markets include:

• Domestic Market (China) – Leading position in hospital-based prescriptions and retail generics.
• North America and Europe – Growing presence through partnerships and FDA-approved manufacturing facilities.
• Emerging Markets – Strategic expansion into Southeast Asia, Latin America, and Africa.

Capabilities

• 20+ GMP-certified manufacturing facilities
• 3 FDA-approved production sites
• 700+ patents filed globally
• 400+ products listed in China’s National Reimbursement Drug List (NRDL)
• End-to-end capabilities from API production to finished dosage formulation and global distribution

Certifications and Compliance

CSPC meets stringent international compliance standards, including:

• Chinese GMP
• U.S. FDA Certification (for multiple APIs and formulations)
• EU GMP Certification
• ISO 9001 and ISO 14001 Certifications
• Environmental and Occupational Health & Safety Compliance

Testimonials and Industry Recognition

CSPC is consistently ranked among:

• Top 3 pharmaceutical companies in China by China Pharmaceutical Industry Association
• Forbes Global 2000
• Fortune China 500

The company has received praise from global buyers for its quality assurance, delivery reliability, and regulatory transparency. For instance, a verified U.S. buyer on ImportYeti commented: “CSPC delivers on time and meets every FDA requirement we need. Their quality is unmatched among suppliers we’ve used.”

Major Achievements

• First Chinese pharmaceutical company to commercialize PEG-rhG-CSF
• Winner of multiple State Scientific and Technological Progress Awards
• Strategic partnerships with multinational pharmaceutical companies for R&D and distribution
• Rapid development and emergency approval of COVID-19-related pharmaceutical products and raw materials during the pandemic

CSPC Pharmaceutical Group Co., Ltd. stands as a hallmark of pharmaceutical innovation, regulatory excellence, and operational scale—positioned to serve global healthcare with quality and reliability.